Objective:To explore the correlation between enhanced CT quantitative parameters and malignant biological behavior and prognosis of colon cancer.Methods:From February 2017 to October 2019, 100 patients with colon cancer in Anhui Wanbei Coal-Electrivity Group Gernal Hospital were selected as the research subjects, and all performed enhanced CT examination. The serum tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) levels were detected. According the mean value of CEA, CA19-9, the patients were divided into different group, and CEA< 28.36 pmol/L was considered to below level, ≥ 28.36 pmol/L was high; CA19-9<40.26 pmol/L was considered to below level, ≥ 40.26 pmol/L was high. The quantitative parameters of enhanced CT in patients with colon cancer with different serum CEA and CA19-9 levels and different pathological indicators (CT scan value, enhanced value, degree of enhancement) were compared. The correlation between serum tumor marker levels, malignant biological behavior of colon cancer and quantitative parameters of enhanced CT were explored. After 12-months′ followed-up, the clinical data of patients with different prognosis and enhanced CT parameters were counted. The factors affecting the prognosis of colon cancer patients and the predictive value of enhanced CT quantitative parameters on the prognosis of patients were explored.Results:The CT scan value, enhancement value and enhancement degree of colon cancer patients with low levels of serum CEA and CA19-9 were lower than those with high levels: (30.16 ± 5.14) HU vs. (38.51 ± 5.72) HU, (55.74 ± 8.12)HU vs. (78.62 ± 8.97) HU, (25.58 ± 3.60) HU vs. (40.11 ± 3.14) HU, the differences were statistically significant ( P<0.05). There was a positive correlation between serum CEA and CA19-9 levels in patients with colon cancer and CT scan value, enhancement value, and degree of enhancement ( P<0.05). The CT enhancement value and enhancement degree of colon cancer patients were related to Dukes staging, differentiation degree, lymph node metastasis and lymphatic infiltration in colon cancer patients. The CT scan value was related to Dukes staging, lymph node metastasis and lymphatic infiltration of colon cancer patients ( P<0.05). The risk factors for death of colon cancer patients included age, Dukes staging, degree of differentiation, lymph node metastasis, lymphatic invasion, CT scan value, enhancement value, and degree of enhancement ( P<0.05). The area under the curve (AUC) of CT scan value, enhancement value, and enhancement degree combined to predict the prognosis of colon cancer patients was 0.873, which was greater than the single prediction of each parameter. The best sensitivity and specificity of combined prediction were 76.92% and 88.37%, respectively. Conclusions:There is a certain correlation between the enhanced CT quantitative parameters and the malignant biological behavior of patients with colon cancer. The increased detection value is risk factor for the prognosis.

The aim of the present study was to examine the effects of suppression of EphB4 and/or mTOR on the biological behaviors of ovarian cancer cells, and the potential regulatory pathways. Antisense EphB4 vectors and shRNA vectors targeting mammalian target of rapamycin (mTOR) were constructed and transfected into A2780 and SKOV3 cells (two ovarian cancer cell lines). The effects of the antisense EphB4 vectors and the shRNA vectors on the proliferation, apoptosis and invasion of ovarian cancer cells were measured, and the expression of EphB4, mTOR and Akt detected. The results showed that transfection with mTOR shRNA could inhibit growth, induce apoptosis, and reduce invasive ability of ovarian cancer cells, which was accompanied by downregulation of EphB4, mTOR and Akt. The inhibitory effects on cell growth caused by mTOR shRNA alone were weaker than those by antisense pEGFP-C1-EphB4. In the antisense pEGFP-C1-EphB4-transfected cells, it was found that EphB4 knockdown could decrease the mTOR expression and slightly reduce the Akt phosphorylation. Significant suppressive effects on cell growth were observed in cells co-transfected with antisense pEGFP-C1-EphB4 and mTOR shRNA. In co-transfection group, the expression levels of EphB4, mTOR and Akt were distinctly lower than those in other groups. It was concluded that suppression of EphB4 may inhibit the growth of ovarian cancer cells by downregulation of the PI3K/Akt/mTOR pathway, and reverse Akt phosphorylation induced by mTOR shRNA. Inhibition of EphB4 and mTOR combined may cooperatively suppress the biological behaviors of ovarian cancer cells.

The aim of the present study was to examine the effects of suppression of EphB4 and/or mTOR on the biological behaviors of ovarian cancer cells, and the potential regulatory pathways. Antisense EphB4 vectors and shRNA vectors targeting mammalian target of rapamycin (mTOR) were constructed and transfected into A2780 and SKOV3 cells (two ovarian cancer cell lines). The effects of the antisense EphB4 vectors and the shRNA vectors on the proliferation, apoptosis and invasion of ovarian cancer cells were measured, and the expression of EphB4, mTOR and Akt detected. The results showed that transfection with mTOR shRNA could inhibit growth, induce apoptosis, and reduce invasive ability of ovarian cancer cells, which was accompanied by downregulation of EphB4, mTOR and Akt. The inhibitory effects on cell growth caused by mTOR shRNA alone were weaker than those by antisense pEGFP-C1-EphB4. In the antisense pEGFP-C1-EphB4-transfected cells, it was found that EphB4 knockdown could decrease the mTOR expression and slightly reduce the Akt phosphorylation. Significant suppressive effects on cell growth were observed in cells co-transfected with antisense pEGFP-C1-EphB4 and mTOR shRNA. In co-transfection group, the expression levels of EphB4, mTOR and Akt were distinctly lower than those in other groups. It was concluded that suppression of EphB4 may inhibit the growth of ovarian cancer cells by downregulation of the PI3K/Akt/mTOR pathway, and reverse Akt phosphorylation induced by mTOR shRNA. Inhibition of EphB4 and mTOR combined may cooperatively suppress the biological behaviors of ovarian cancer cells.
Apoptosis ; genetics ; Cell Line, Tumor ; Cell Proliferation ; Down-Regulation ; genetics ; Female ; Humans ; Ovarian Neoplasms ; pathology ; physiopathology ; Proto-Oncogene Proteins c-akt ; genetics ; metabolism ; RNA, Small Interfering ; genetics ; Receptor, EphB4 ; genetics ; metabolism ; Suppression, Genetic ; genetics

We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB-IIA) cervical cancer having risk factors after surgery. The condition was assessed in terms of prognosis, adverse effects, and quality of life. This randomized trial involved nine centers across China. Eligible patients were randomized to receive adjuvant chemotherapy or CCRT after surgery. The primary end-point was progression-free survival (PFS). From December 2012 to December 2014, 337 patients were subjected to randomization. Final analysis included 329 patients, including 165 in the adjuvant chemotherapy group and 164 in the adjuvant CCRT group. The median follow-up was 72.1 months. The three-year PFS rates were both 91.9%, and the five-year OS was 90.6% versus 90.0% in adjuvant chemotherapy and CCRT groups, respectively. No significant differences were observed in the PFS or OS between groups. The adjusted HR for PFS was 0.854 (95% confidence interval 0.415-1.757; P = 0.667) favoring adjuvant chemotherapy, excluding the predefined non-inferiority boundary of 1.9. The chemotherapy group showed a tendency toward good quality of life. In comparison with post-operative adjuvant CCRT, adjuvant chemotherapy treatment showed non-inferior efficacy in patients with early-stage cervical cancer having pathological risk factors. Adjuvant chemotherapy alone is a favorable alternative post-operative treatment.
Female ; Humans ; Uterine Cervical Neoplasms/drug therapy* ; Prospective Studies ; Quality of Life ; Neoplasm Staging ; Chemoradiotherapy ; Chemotherapy, Adjuvant/adverse effects* ; Adjuvants, Immunologic ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Retrospective Studies